Advancements in CLL Treatment: Comparing BTK Inhibitors and Understanding Survival Mechanisms

This chapter examines the ALPINE trial's results, showcasing the enhanced efficacy and safety of zanubrutinib over ibrutinib for chronic lymphocytic leukemia. It also delves into the genetic aspects of blood types and the adaptive mechanisms of CLL cells that contribute to resistance against venetoclax therapy.